Literature DB >> 27614164

No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT.

F Killander1, P Karlsson2, H Anderson3, J Mattsson4, E Holmberg5, D Lundstedt2, L Holmberg6, P Malmström7.   

Abstract

BACKGROUND: Breast-conserving surgery (BCS) followed by radiotherapy (RT) is an established treatment for women with T1-2N0 breast cancers. Since subgroups of patients have low ipsilateral breast tumour recurrence (IBTR) rates, it is important to study whether RT is necessary for all patients. PATIENTS AND METHODS: A total of 1187 women with primary T1-2N0M0 breast cancer were randomised, after standardised sector resection, to postoperative whole breast RT or no local treatment. Adjuvant systemic therapy was offered to patients with stage II cancers. Patients were followed with clinical examinations and annual mammography for 10 years and thereafter referred to the Swedish mammography screening program.
RESULTS: After 15 years of follow-up, a higher cumulative incidence of IBTR was observed in control patients, 23.9%, versus irradiated patients, 11.5%, P<0.001. Recurrence-free survival was inferior, 51.7% versus 60.4%, P=0.0013. The main effect of RT was seen during the first 5 years. However, overall survival was not significantly lower 68.4% versus 71.1%, P=0.68, nor was breast cancer-specific mortality significantly higher.
CONCLUSIONS: RT after BCS significantly reduced the incidence of IBTR at 15 years of follow-up. We were unable to identify subgroups which could be spared RT. Breast cancer mortality was not significantly reduced after RT. Good predictive markers for radiation sensitivity and improved adjuvant systemic therapy are needed to omit RT after BCS.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Breast-conserving surgery; Contralateral breast cancer; Ipsilateral breast tumour recurrence; Randomised trial; Whole breast radiation

Mesh:

Substances:

Year:  2016        PMID: 27614164     DOI: 10.1016/j.ejca.2016.08.001

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  21 in total

1.  A Network Meta-Analysis of Surgical Treatment in Patients With Early Breast Cancer.

Authors:  Yu Gui; Xunzhou Liu; Xianchun Chen; Xi Yang; Shichao Li; Qingwen Pan; Xiangdong Luo; Li Chen
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

Review 2.  Evolution of radiotherapy techniques in breast conservation treatment.

Authors:  John Boyages; Lesley Baker
Journal:  Gland Surg       Date:  2018-12

Review 3.  Omission of adjuvant radiotherapy for older adults with early-stage breast cancer particularly in the COVID era: A literature review (on the behalf of Italian Association of Radiotherapy and Clinical Oncology).

Authors:  Isabella Palumbo; Simona Borghesi; Fabiana Gregucci; Sara Falivene; Antonella Fontana; Cynthia Aristei; Antonella Ciabattoni
Journal:  J Geriatr Oncol       Date:  2021-05-18       Impact factor: 3.599

Review 4.  Is invasion a necessary step for metastases in breast cancer?

Authors:  Steven A Narod; Victoria Sopik
Journal:  Breast Cancer Res Treat       Date:  2018-01-20       Impact factor: 4.872

5.  Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.

Authors:  Martin Sjöström; Johan Staaf; Patrik Edén; Fredrik Wärnberg; Jonas Bergh; Per Malmström; Mårten Fernö; Emma Niméus; Irma Fredriksson
Journal:  Breast Cancer Res       Date:  2018-07-04       Impact factor: 6.466

6.  Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer.

Authors:  Martin Sjöström; S Laura Chang; Nick Fishbane; Elai Davicioni; Shuang G Zhao; Linda Hartman; Erik Holmberg; Felix Y Feng; Corey W Speers; Lori J Pierce; Per Malmström; Mårten Fernö; Per Karlsson
Journal:  J Clin Oncol       Date:  2019-10-16       Impact factor: 44.544

7.  Omitting radiotherapy is safe in breast cancer patients ≥ 70 years old after breast-conserving surgery without axillary lymph node operation.

Authors:  Ying Zhong; Yali Xu; Yidong Zhou; Feng Mao; Yan Lin; Jinghong Guan; Songjie Shen; Bo Pan; Changjun Wang; Li Peng; Xin Huang; Xuefei Wang; Qiang Sun
Journal:  Sci Rep       Date:  2020-11-10       Impact factor: 4.379

8.  Postoperative radiotherapy for invasive micropapillary carcinoma of the breast: an analysis of Surveillance, Epidemiology, and End Results database.

Authors:  San-Gang Wu; Wen-Wen Zhang; Jia-Yuan Sun; Feng-Yan Li; Yong-Xiong Chen; Zhen-Yu He
Journal:  Cancer Manag Res       Date:  2017-10-03       Impact factor: 3.989

Review 9.  Local and Regional Breast Cancer Recurrences: Salvage Therapy Options in the New Era of Molecular Subtypes.

Authors:  Yazid Belkacemi; Nivin E Hanna; Clementine Besnard; Soufya Majdoul; Joseph Gligorov
Journal:  Front Oncol       Date:  2018-04-17       Impact factor: 6.244

Review 10.  Omission of postoperative radiation after breast conserving surgery: A progressive paradigm shift towards precision medicine.

Authors:  Pierfrancesco Franco; Fiorenza De Rose; Maria Carmen De Santis; Nadia Pasinetti; Valentina Lancellotta; Bruno Meduri; Icro Meattini
Journal:  Clin Transl Radiat Oncol       Date:  2020-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.